R
Rajiv Mundayat
Researcher at Pfizer
Publications - 54
Citations - 1597
Rajiv Mundayat is an academic researcher from Pfizer. The author has contributed to research in topics: Tofacitinib & Ulcerative colitis. The author has an hindex of 12, co-authored 40 publications receiving 1239 citations.
Papers
More filters
Journal ArticleDOI
A multinational population survey of intravaginal ejaculation latency time.
Marcel D. Waldinger,Paul Quinn,Maria Dilleen,Rajiv Mundayat,Dave H. Schweitzer,Mitradev Boolell +5 more
TL;DR: The distribution of the Intravaginal ejaculation latency time (IELT) in all the five countries was positively skewed, with a median IELT of 5.4 minutes but with differences between countries, which was significantly different from each of the other countries.
Journal ArticleDOI
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Mathew S. Maurer,Mazen Hanna,Martha Grogan,Angela Dispenzieri,Ronald M. Witteles,Brian M. Drachman,Daniel P. Judge,Daniel J. Lenihan,Stephen S. Gottlieb,Sanjiv J. Shah,D. Eric Steidley,Hector O. Ventura,Srinivas Murali,Marc A. Silver,Daniel Jacoby,Savitri Fedson,Scott L. Hummel,Arnt V. Kristen,Thibaud Damy,Violaine Planté-Bordeneuve,Teresa Coelho,Rajiv Mundayat,Ole B. Suhr,Márcia Waddington Cruz,Claudio Rapezzi +24 more
TL;DR: In the THAOS registry, ATTR in the United States is overwhelmingly a disorder of older adult male subjects with a cardiac-predominant phenotype, and neurologic phenotypic expression differs between wild-type disease and Val122Ile, but survival from enrollment in ThAOS does not.
Journal ArticleDOI
Development and Validation of a New Questionnaire to Assess Sexual Satisfaction, Control, and Distress Associated with Premature Ejaculation
TL;DR: The Index of Premature Ejaculation is a reliable and valid questionnaire for the assessment of control over ejaculation, satisfaction with sex life, and distress in men with PE and has the potential to add value to interpretations of improvements in ejaculation latency resulting from new treatments of PE.
Journal ArticleDOI
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
Teresa Coelho,Giampaolo Merlini,Christine Bulawa,James Fleming,Daniel P. Judge,Jeffery W. Kelly,Mathew S. Maurer,Violaine Planté-Bordeneuve,Richard Labaudinière,Rajiv Mundayat,Steve Riley,Ilise Lombardo,Pedro E. Huertas +12 more
TL;DR: Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis.
Journal ArticleDOI
Tafamidis in Transthyretin Amyloid Cardiomyopathy: Effects on Transthyretin Stabilization and Clinical Outcomes
Mathew S. Maurer,Donna R. Grogan,Daniel P. Judge,Rajiv Mundayat,Jeff Packman,Ilise Lombardo,Arshed A. Quyyumi,Janske Aarts,Rodney H. Falk +8 more
TL;DR: In this article, a phase 2 open-label trial evaluated the stabilization of TTR tetramers using 20 mg of tafamidis daily at week 6 (primary end point), month 6, and month 12.